76 results
Page 2 of 4
S-4/A
l2w6ekg9
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
425
krck 0mv9mq0fawlwc
9 Jun 23
Business combination disclosure
4:31pm
425
v989ano5kul68
17 May 23
Business combination disclosure
4:54pm
10-Q
1por54eun9sy7 4ejbfd
15 May 23
Quarterly report
4:30pm
S-4
EX-10.9
zio4t gs0fk3cl
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
457zmj
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.11
s6q238 dxq2voixja3n
11 May 23
Registration of securities issued in business combination transactions
9:09am
425
jw3bateugbfphkkoy
18 Apr 23
Business combination disclosure
5:12pm
6-K
EX-99.3
zo71wxbe6uc7s0 g3
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.3
fxbdmahua42s
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.2
q63iu pa5vl9l
2 Jun 22
Notice of Annual General Meeting of Shareholders
5:00pm
6-K
EX-99.3
ub4ta6vedwa2uub
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
424B5
5n3k ksfax2hlbgdyub
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.1
m9yhlkl4debfiod7mj0
5 Oct 21
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
4:17pm
6-K
EX-99.2
0u7unk
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
EX-99.1
nc62qohaa0f5dx
8 Jul 21
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
4:05pm
POS AM
pofzhnsh ntk8rq9g
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
yoularg
19 Apr 21
Prospectus unintentially filed late
5:06pm